Topic
Topic
Late-breaking EADV 2026 data were framed as supporting DecisionDx-Melanoma use in sentinel lymph node biopsy decisions and risk-aligned post-surgical management of melanoma patients.
Late-breaking EADV 2026 data support DecisionDx-Melanoma for SLNB decision-making and risk-aligned post-surgical management of cu…
EADV 2026 late-breaking data support the DecisionDx-Melanoma gene-expression profile test in guiding sentinel lymph node biopsy d…
Amanda Lund's work links lymph node colonization to tumor evolution, adaptation, and immune escape, reframing nodal involvement a…
